Synthesis of new N-(5,6-methylenedioxybenzothiazole-2-yl)-2-[(substituted)thio/piperazine]acetamide/propanamide derivatives and evaluation of their AChE, BChE, and BACE-1 inhibitory activities
| dc.authorid | 0000-0002-8651-826X | |
| dc.authorid | 0009-0002-1614-2380 | |
| dc.authorid | 0000-0003-4038-8823 | |
| dc.contributor.author | Tutus, Beyzanur | |
| dc.contributor.author | Kaya, Aybuke Zuleyha | |
| dc.contributor.author | Baz, Yonca | |
| dc.contributor.author | Evren, Asaf Evrim | |
| dc.contributor.author | Ozkan, Beguem Nurpelin Saglik | |
| dc.contributor.author | Yurttas, Leyla | |
| dc.date.accessioned | 2025-05-20T19:00:04Z | |
| dc.date.issued | 2024 | |
| dc.department | Bilecik Şeyh Edebali Üniversitesi | |
| dc.description.abstract | In this study, the synthesis of N-(5,6-methylenedioxybenzothiazole-2-yl)-2-[(substituted)thio/piperazine]acetamide/propanamide derivatives (3a-3k) and to investigate their acetylcholinesterase (AChE), butyrylcholinesterase (BChE) and beta-secretase 1 (BACE-1) inhibition activity were aimed. Mass, H-1 NMR, and C-13 NMR spectra were utilized to determine the structure of the synthesized compounds. Compounds 3b, 3c, 3f, and 3j showed AChE inhibitory activity which compound 3c (IC50 = 0.030 +/- 0.001 mu M) showed AChE inhibitory activity as high as the reference drug donepezil (IC50 = 0.0201 +/- 0.0010 mu M). Conversely, none of the compounds showed BChE activity. Compounds 3c and 3j showed the highest BACE-1 inhibitory activity and IC50 value was found as 0.119 +/- 0.004 mu M for compound 3j whereas IC50 value was 0.110 +/- 0.005 mu M for donepezil, which is one of the reference substance. Molecular docking studies have been carried out using the data retrieved from the server of the Protein Data Bank (PDBID: 4EY7 and 2ZJM). Using in silico approach behavior active compounds (3c and 3j) and their binding modes clarified. | |
| dc.identifier.doi | 10.1002/ddr.22214 | |
| dc.identifier.issn | 0272-4391 | |
| dc.identifier.issn | 1098-2299 | |
| dc.identifier.issue | 4 | |
| dc.identifier.pmid | 38816986 | |
| dc.identifier.scopus | 2-s2.0-85195013789 | |
| dc.identifier.scopusquality | Q2 | |
| dc.identifier.uri | https://doi.org/10.1002/ddr.22214 | |
| dc.identifier.uri | https://hdl.handle.net/11552/8784 | |
| dc.identifier.volume | 85 | |
| dc.identifier.wos | WOS:001235816600001 | |
| dc.identifier.wosquality | Q2 | |
| dc.indekslendigikaynak | WoS | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.indekslendigikaynak | WoS - Science Citation Index Expanded | |
| dc.language.iso | en | |
| dc.publisher | Wiley | |
| dc.relation.ispartof | Drug Development Research | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.snmz | KA_WOS_20250518 | |
| dc.subject | Alzheimer Disease (AD) | |
| dc.subject | Benzothiazole | |
| dc.subject | Cholinesterase Inhibitors | |
| dc.subject | Beta-Secretase (BACE-1) | |
| dc.title | Synthesis of new N-(5,6-methylenedioxybenzothiazole-2-yl)-2-[(substituted)thio/piperazine]acetamide/propanamide derivatives and evaluation of their AChE, BChE, and BACE-1 inhibitory activities | |
| dc.type | Article |
Dosyalar
Orijinal paket
1 - 1 / 1












